Answered You can buy a ready-made answer or pick a professional tutor to order an original one.
Propose a topic and write a 7 page paper on a current topic of dispute, controversy, or complexity that is ripe for Congress, FDA or pharmaceutical industry. This paper will analyze an emerging regula
Propose a topic and write a 7 page paper on a current topic of dispute, controversy, or complexity that is ripe for Congress, FDA or pharmaceutical industry. This paper will analyze an emerging regulatory issue of the group’s choice and explain the legal, policy, and business implications of the issue, including but not limited to:
• Issue: Identify the emerging issue and policy concern(s) and explain the reason this issue is a current challenge.
• Rule: What are the current statutes, regulations or guidance documents applicable to this emerging issue. • Analysis: What is the appropriate resolution of this emerging issue, what are the pros and cons of a course of action (COA), who are the stakeholders involved and how would you balance their respective interests.
• Conclusion: Make a final recommendation(s) to resolve the issue in the future, detailing what action should be taken by whom.
- @
- 1030 orders completed
- ANSWER
-
Tutor has posted answer for $50.00. See answer's preview
************************* ** *** *** towards *** ***** ************* ** Student:Institution of ***************************************** Regulations on Off-Label **** ************** *** label **** *** ** the ***** ** * drug *** ********** ******** ** ***** ** for unapproved ******* ****** or ***** ** in ********** ******* ** ******* a drug the *** ******** a *** ** ****** *** ******** ******** which shows that *** patient ** ********** **** ** ******** *** **** ** ******** *** * specific ********** after substantial evaluation *** *** ******* visibility ** how it's ***** **** ** the ***** *** **** *** ********** ******** ** ** ********** ******* ****** ** might lead ** ******* events For **** years the *** has prohibited *** promotion ** off ***** ***** ******** ** has **** ********** in ***** *** *** lost * court **** ** *** regulation of ********* *** non-misleading" ****** FDA is ********* taking ******** initiatives to regulate *** ***** ********** *** uses ** **** ***** ** **** ******* **** ** the regulations *** *********** *** ** ****** to prevent off ***** drug ********** *** where ** *** ** ************************************* ***** ********* ****** **** **** ********* promote ***** *** **** ******* *** ******** of *** **** *** Drug ************** *** **** *** **** ************** *** *** **** obligation of ******* *** marketing of pharmaceutical products **** ***** drug ********* **** ************ ** promoting * **** **** ** *** *** **** ******** ** *** ****** ********* ********** *** involve ************ drugs ** **** as *** over the counter ***** *** ******** violates ******* and ****** ********** ********* drug use *** ***** liabilities *** ******* ****** ***** ** *** long *** *** ********* the ****** of *** ******** by ******** **** *** ***** sold ** *** public ** not **** ****** ***** *** ************* ** the **** ** essential Multiple *********** have been ***** ** *** FDA ** regulate ********* promotions ** well ** the uses Various *********** **** been ********* ** ** part ** the solutions ** *** ******* ******* (Robertson & ********** ***** **** *** paper **** ********* *** **** of *** *** ** regulating ********* ************* ***** on ********* ************ FDA *** authority on *** drugs sold ** *** ****** ****** ***** *** considered based on *** uses *** ******** use ** ********* cure treatment ** **** ** ********** ** disease ** **** ******* * drug Ideally * ********* can ** * **** ** **** ************* *** **** ** *** ***** *********** the **** *************** ** ********** ** it ************* ********** ** ***** *** ***** ******* *** ******* of *** *** ** be **** in *** ****** ****** *** *** ******** *** ********** a ************ ***** on *** ******* ** ***** ******* ** *** * particular ****** **** ******** ******* practitioners **** *** authority ** ********* the ********** Practitioners **** the liberty ** ********* ******** ***** ******* instances ** which a **** ************ promotes ********** drugs ***** ** ********** ** *** **** *** FDCA *** ******* provisions **** ******** off-label ********** *** marketing ** ********** or misbranded ***** ** the ********** ***** ** prohibited and this can result ** criminal *** ***** ********* *** ********* ********* ***** *** **** *** *** *********** ** **** a **** should ** used for *** ******** *** **** ******** as ********* ** *** drug labeling criteria **** ********** ***** *** concerning off-label **** *** *** deems * drug ** be ********** ** ** ***** adequate directions *** *** intended ******* ***** ******** *** *** ***** **** **** as **** ********** **** ******* paths *** **** *** *** approved by *** *** (Zettler 2017) * drug is ********** from *** promotion ** the **** ************* ******* *** FDCA ************* regulation ** ********* promotionAccording ** the *** ******** * drug is subject to promotion ** ** is ******** non-misleading *** ***** *********** information on ***** ******* side ******* The *** ********* **** ************* from ********* ** advertising drugs **** **** not been approved ** the ****** The *** ******** *********** ** *** implementation ** legislative practices ************ ********* *** ******** ** *********** *** *********** that ******* ** ********* uses ** *** ******* ***** *** ******** **** *** ********* ** ******* ** unsolicited ******** **** arise from ****** care professionals *** ******** ****** ** ** *** ********** **** *********** ******* ************* *** ******* instances ** ********** ******* education ********** ****** the ******* of the **** *** **** Administration Modernization *** of **** ******* ***** were ******* ********* **** ******** *** ******** ******** guidelines *** drug *** by * health **** professional (Robertson ***** Kesselheim ***** **** the FDA *** ****** to **** an ********* ****** ** *** ****** **** industrySection ** *** FDAMA ****** that ********* **** ****** to share ****** **** economic *********** ******* ******** **** ** ***** ********* *** ******** ** ***** with formulary ********** ******* **** ** ************* ** well ** ***** organizations that **** ********* ****** ******** and ************* ** ******** off-labeling *** FDA ***** *** ******** ** **** ** *** ******* **** there ** ************* on ***** ***** ****** ** ******** ******** ********* **** *** ******* ********** ********* over *** ******* ** civil and ******** fines **** other ************** ********* for being involved ** ************ ********** *** ******* ***** *** * case of *************** ***** *** fined ** *** ******* government ** ********* promotion of most ** *** drugs *** ** ********* ****** ****** **** ***** ********** ***** **** *** regulations ** the federal ********** ensure **** off-label ********* ****** ** ***** **** ** not **** implicationsThe ****** care ****** *** *** * ******* focus ** ensuring **** ********* ********* ** *** guidelines ********** have the ********* ** ********* ***** ******* *** ******** of *** ***** ** what ******* a great **** ******* *** FDA ********* ********* promotions ***** ** * **** to note **** ********* ************* can ** considered ********* ** ******* depending ** *** ******** ******** **** sufficient evidence ** ******** on an off-label **** ** is ******* *** *** ************ *** legal limits **** proved ********* *** ***** ********* protection has focused on some ********* ********* The federal ****** **** imposed penalties on ********* **** ******* *** ********* ********* **** ****** **** ******** *** ***** amendment ******* that ***** is freedom ** ****** ********** *** ****** **** ***** are no misleading ****** ** health **** ******* ** al ***** **** of *** ********* *** *** ***** ******* boards ** to ******* ************ **** the practice ** ******** ** the ****** has ********* ******** ** ********* promotion and ***** ** off-label protection to **** ***** However this ******* ** ******** products **** of the **** ******** that the ******* ****** ** lawful ******* product ****** **** ***** on ****** ********* ** ******* ** regulatory ******** *** ******* ****** ****** ** ************* ** a *** ** ******** **** ***** ******** ********** ******** that ******* ** the ******* ******* ********* ********* ** ******* ** *********** ********* use can **** ***** *********** ** *** **** of ********* *** ******** charges The ************** protection ** commercial speech *** *** to ********** ** ********* promotions *** *** legal liabilities **** *** been *********** (Kim ***** ********** 2017) Arguments *** ***** ***** **** *** ****** *** * right ** ******** as **** ** *** safety ************** ** *** ***** **** highlight *** ***** ************ ** ********* ********** are **** ** ****** *********** * ************** ******* The legalities ** the incident led ** * ********** between the ******* *** *** *** *** ******* had *** ******** product ***** ** ***** to lower *** levels of ***** triglyceride *** ********* allowed the company ** engage in ************** ********** ** *** ******** for ********* **** ** ********** the **** ******* **** ** *** *** ** **** ** *** ****** ******* **** the **** ********* of ******** **** ***** are ********* **** promotions (Mackey ***** ***** ***** **** * **** represents *** ******** preclearance ********* ***** ** *** *** as * *** ** *********** ********* ********** ***** **** **** ********* **** ***** ********* may also go ** court in ******* ** ***** ******** **** may ****** *** regulation ** other *** ***** *********** activities **** ***** ***** ********** in *** ********** ** *** ***** ******************** programs such ** the federal ***** ****** *** *** *** ************* statutes were ****** ** ***** ** ********* promotions *** laws were passed to ****** **** there ** ********** from companies ****** ******** ** well ** officers *** policies *** ********** ******** ** ********* compliance ******* ******* on *** ******* ************** ******* ** ****** **** there is * ************ ** ***** for off-label **** However this should be **** **** *** ********* ** *** policies *** ********** *** implementation ** ****** ******** ** **** ** * **** **** *** impact *********** ******* **** *** ********* and ***** health ************* ****** **** the FDA ******** ** can **** ********* ********** There is an increasing **** to ***** on the safety ** *** people before involvement ** ****** **** malpractice ********** ********** **** ******* drugs that **** *** **** approved by the *** is an indication ** ************* in *** ****** ****** ******* ***** **** *** ******* ***** ****** *** *** ************* ******** **** ********* ** ********** ********** ************* *** ******* *********** ********** ********* due ** *** promotion ***** *** ******** by *** *** ***** and ******* *********** *** ****** ******** in ******** that *** ********* does *** ****** ****** ****** Part ** the measures by *** ***** *** ******* **** ** *** ********* ***** ** the ************** ************* ** *** they ****** ******* their ****** ** ****** that **** ** *** ******* ***** which *** *** *** certified ** the **** and ***** *** ********* communication that ******* ** ******** *********** ********** *** measures by the ********** ******* ****** **** **** been ******** ** ****** that ********* ** not ********* ********* habits Establishing **** ** ******** ********* on drugs which are ******** used *** ********* **** ** ********* Part ** *** ****** involves ********* which *** ****** *********** **** ****** **** ***** ** ** ***** regulatory board that has ****** ** ******** failing renewing ** **** as taking action against *** ************** ************ **** ******* ** *** ******** ********* ** ***** for ********* uses *** *** was **** ** * **** **** ***** ******* *** issues ** ********* uses and *********** ** *** ***** ******** states ***** ****** the *** **** the sole ********* of ******* ************ on *** ************ **** by *** pharmaceutical ************* with ******** **** **** *** ********* ** prescribe *** **** ******* payments Findings ******** **** pharmaceutical marketing ***** **** during payor coverage *** ********* *********** ********* **** ** *** **** ******* ******** ** ******** ******** fines *** penalties ** ************* **** ***** medicines **** **** ******** ** essential to ******* ********* ** ********* ********* ************ ** ************* can **** ***** ***** of promotion ** ********* *** **** ************** **** ******* the ****** ** **** risks ** the ******* *** ******** ** *** ********* the ****** and **** *** ******** ** *** **** run **** ****** **** ********* ************* ** *********** in ********* promotion ** a ********** ****** ******** ***** *** ********* *** required to **** ***** * specific ******** ***** **** not hamper the ***** ******* standardsThe standards ****** ******** **** ******** ** **** as *** ****** ****** *** drug The ************* ********* the ****** of ********** trials and *** ******** ********* When ********** are **** ** the ********* promotions ** *** ****** *** **** ***** ** ********* ******* **** *** be **** **** *** *** *** ******** *** drugs ****** studies postulate **** ***** ** * lack ** ******** on *** effectiveness ** *** ***** which **** ********** **** There is * **** *** collecting **** that ******* ** the effectiveness ** *** **** ****** ******** ** *** use **** ******** ************** *** ********** *** **** **** *** reduce ********* ** off-label *** The challenges ***** have led ** *** ***** incorporating **** **** ** *** ***** ** ********** ***** ** * need for the *** ** make * ******** review of the data ** ******** *** ***** *** ******** **** **** **** ******* **** ******** 2018) **** *** **** ** *********** approval decisionsConclusionThe ********** ***** ** ********* ********* *** ** solved **** **** ***** imposes ***** rules **** the ***** *** stiff ** *** scare away companies **** are ******** ** ********* ********* *** *** *** *** **** ********** of ensuring that *** ***** sold do *** have health ******* **** ******** ** done ** can **** ********* to *** ****** The **** of ****** ******** *** ** *** ******** ***** ** ****** ** ********* *** ***** ** *** off-label promotion before ******** a *** Controlled ****** *** ******** *** ***** ********* *** FDA's loss ** *** ***** *** ******* ********* *** ******* ** ****** accurate information *** ruling ** *** court *** * *** **** ** *** *** *** ****** *********** ****** ** ****** **** *** measures ** ******** ******** off-label ********* *** federal government should support *** **** ** place ******* by the ******* ********** ** ******** ********* laws *** help *** ******** *** ********** Thus there ** * **** *** the ****** and ********** as * way ** Supporting *** FDA References Herbst * * ******** * * ******* * E & ****** * ****** ***** ********* ********** of Evidence-Based ********* of ************ ****** * ***** of ********* ******** ******** ********** ********* ********* ** the USA Pharmaceutical ******** ***** ********** J ***** Kapczynski * ****** Promotion ** ***** *** ********* ***** *** ** **** and **** ************** at * crossroadsJAMA internal ************** ************* * * ****** ***** ******* *** ****** ********* Drug *********** and *** ****** ** *** ***** ***** ****** Act **** ***** **** LJ ** 401Mackey * * ***** ***** * * ***** June) After Amarin v **** **** **** *** ****** **** *** off-label promotion *********** In **** ****** *********** **** ** No * ** ******** ***************** C ***** ********** * * ****** Regulating Off-Label Promotion-A Critical ******* New ******* ******* ** medicine375(24) *********** Brennan (2018) ********* ********** *** FDA's Rules ***** ** Unravel? ********* ** ******** ** 2020 Retrieved **** ***************************************************************************************************************** * * (2017) The Indirect ************ of ******** ********* ************* ** LJ78 ****
